{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:12Z","timestamp":1784822592527,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in collaboration with Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00934-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:46:12Z","timestamp":1776440772000},"page":"1523-1537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden Among Caregivers of Adult Patients with Neurofibromatosis Type 1 and Plexiform Neurofibroma in the United States: A Cross-Sectional Survey Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1806-1592","authenticated-orcid":false,"given":"Xiaoqin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Cunnington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Dettling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Pfefferkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Young-Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"4","key":"934_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/13543784.2013.772979","volume":"22","author":"DH Gutmann","year":"2013","unstructured":"Gutmann DH, et al. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22(4):443\u201362.","journal-title":"Expert Opin Investig Drugs"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","volume":"12","author":"CL Monroe","year":"2017","unstructured":"Monroe CL, Dahiya S, Gutmann DH. Dissecting clinical heterogeneity in neurofibromatosis type 1. Annu Rev Pathol Mech Dis. 2017;12:53\u201374.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"12","key":"934_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20(12):1643\u201351.","journal-title":"Neuro Oncol"},{"issue":"32","key":"934_CR4","doi-asserted-by":"publisher","first-page":"22571","DOI":"10.18632\/oncotarget.25181","volume":"9","author":"EJ Kahen","year":"2018","unstructured":"Kahen EJ, et al. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget. 2018;9(32):22571\u201385.","journal-title":"Oncotarget"},{"issue":"3","key":"934_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cancers13030463","volume":"13","author":"B Ozarslan","year":"2021","unstructured":"Ozarslan B, et al. Cutaneous findings in neurofibromatosis type 1. Cancers. 2021;13(3):463.","journal-title":"Cancers"},{"issue":"11","key":"934_CR6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344.","journal-title":"Neuro Oncol"},{"issue":"3","key":"934_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.bpo.0000217719.10728.39","volume":"26","author":"AH Crawford","year":"2006","unstructured":"Crawford AH, Schorry EK. Neurofibromatosis update. J Pediatr Orthop. 2006;26(3):413\u201323.","journal-title":"J Pediatr Orthop"},{"key":"934_CR8","volume-title":"Neurofibromatosis 1 synonyms: NF1, von recklinghausen disease, von recklinghausen's neurofibromatosis. GeneReviews\u00ae","author":"JM Friedman","year":"1993","unstructured":"Friedman JM. Neurofibromatosis 1 synonyms: NF1, von recklinghausen disease, von recklinghausen\u2019s neurofibromatosis. GeneReviews\u00ae. Seattle: University of Washington; 1993."},{"key":"934_CR9","unstructured":"National Cancer Institute. Selumetinib continues to show promise in children with NF1. 2018 [cited 2023 Sept 6]. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/selumetinib-nf1-neurofibromas."},{"issue":"5","key":"934_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","volume":"131","author":"MN Needle","year":"1997","unstructured":"Needle MN, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children\u2019s Hospital of Philadelphia experience, 1974\u20131994. J Pediatr. 1997;131(5):678\u201382.","journal-title":"J Pediatr"},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jpeds.2018.10.019","volume":"206","author":"J-S Lai","year":"2019","unstructured":"Lai J-S, et al. Patient reported outcomes measurement information system and quality of life in neurological disorders measurement system to evaluate quality of life for children and adolescents with neurofibromatosis type 1 associated plexiform neurofibroma. J Pediatr. 2019;206:190\u20136.","journal-title":"J Pediatr"},{"issue":"6","key":"934_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1053\/jpdn.2000.16709","volume":"15","author":"KR Chou","year":"2000","unstructured":"Chou KR. Caregiver burden: a concept analysis. J Pediatr Nurs. 2000;15(6):398\u2013407.","journal-title":"J Pediatr Nurs"},{"issue":"4","key":"934_CR13","first-page":"438","volume":"7","author":"Z Liu","year":"2020","unstructured":"Liu Z, Heffernan C, Tan J. Caregiver burden: a concept analysis. Int J Nurs Sci. 2020;7(4):438\u201345.","journal-title":"Int J Nurs Sci"},{"issue":"3","key":"934_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ijnurstu.2012.10.005","volume":"50","author":"M Bastawrous","year":"2013","unstructured":"Bastawrous M. Caregiver burden\u2014a critical discussion. Int J Nurs Stud. 2013;50(3):431\u201341.","journal-title":"Int J Nurs Stud"},{"issue":"8","key":"934_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","volume":"38","author":"X Yang","year":"2022","unstructured":"Yang X, et al. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. Childs Nerv Syst. 2022;38(8):1513\u201322.","journal-title":"Childs Nerv Syst"},{"key":"934_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.117375","volume":"363","author":"N Das","year":"2024","unstructured":"Das N, et al. Absenteeism and presenteeism among caregivers of chronic diseases: a systematic review and meta-analysis. Soc Sci Med. 2024;363:117375.","journal-title":"Soc Sci Med"},{"issue":"6","key":"934_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/j.1524-4733.2009.00542.x","volume":"12","author":"ER Giovannetti","year":"2009","unstructured":"Giovannetti ER, et al. Construct validity of the Work Productivity and Activity Impairment questionnaire across informal caregivers of chronically ill older patients. Value Health. 2009;12(6):1011\u20137.","journal-title":"Value Health"},{"issue":"1","key":"934_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/0891988720968263","volume":"35","author":"S Kalampokini","year":"2022","unstructured":"Kalampokini S, et al. Caregiver burden in late-stage Parkinsonism and its associations. J Geriatr Psychiatry Neurol. 2022;35(1):110\u201320.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"10","key":"934_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/JGP.0b013e3181d5745d","volume":"18","author":"S Mohamed","year":"2010","unstructured":"Mohamed S, et al. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010;18(10):917\u201327.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"934_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/geront\/41.5.652","volume":"41","author":"M B\u00e9dard","year":"2001","unstructured":"B\u00e9dard M, et al. The Zarit Burden Interview: a new short version and screening version. Gerontologist. 2001;41(5):652\u20137.","journal-title":"Gerontologist"},{"issue":"6","key":"934_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/13607860701529965","volume":"11","author":"YG Bachner","year":"2007","unstructured":"Bachner YG, O\u2019Rourke N. Reliability generalization of responses by care providers to the Zarit Burden Interview. Aging Ment Health. 2007;11(6):678\u201385.","journal-title":"Aging Ment Health"},{"issue":"3","key":"934_CR22","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40120-022-00365-5","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang X, et al. Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States: a cross-sectional study. Neurol Ther. 2022;11(3):1221\u201333.","journal-title":"Neurol Ther"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"issue":"8","key":"934_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341.","journal-title":"Value Health"},{"issue":"1","key":"934_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/10178","volume":"21","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, et al. EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study. J Med Internet Res. 2019;21(1):e10178.","journal-title":"J Med Internet Res"},{"issue":"1","key":"934_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1041610210000785","volume":"23","author":"N Bergvall","year":"2011","unstructured":"Bergvall N, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer\u2019s disease. Int Psychogeriatr. 2011;23(1):73\u201385.","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"934_CR27","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/healthcare12101002","volume":"12","author":"JY Choi","year":"2024","unstructured":"Choi JY, Lee SH, Yu S. Exploring factors influencing caregiver burden: a systematic review of family caregivers of older adults with chronic illness in local communities. Healthcare. 2024;12(10):1002.","journal-title":"Healthcare"},{"issue":"1","key":"934_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12883-023-03429-7","volume":"23","author":"HK Yoo","year":"2023","unstructured":"Yoo HK, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023;23(1):419.","journal-title":"BMC Neurol"},{"key":"934_CR29","first-page":"1793","volume":"10","author":"V Ganapathy","year":"2015","unstructured":"Ganapathy V, et al. Caregiver burden, productivity loss, and indirect costs associated with caring for patients with poststroke spasticity. Clin Interv Aging. 2015;10:1793\u20131802.","journal-title":"Clin Interv Aging"},{"key":"934_CR30","unstructured":"U.S. Bureau of Labor Statistics. Civilian labor force participation rate by age, sex, race, and ethnicity. Employment Projections program. [cited 2026 Mar 13]. https:\/\/www.bls.gov\/emp\/tables\/civilian-labor-force-participation-rate.htm. Accessed 13 Mar 2026."},{"issue":"10","key":"934_CR31","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s11136-024-03737-6","volume":"33","author":"V Sokolova","year":"2024","unstructured":"Sokolova V, et al. Assessing the psychometric performance of the EQ-5D-5L among informal caregivers of people with dementia. Qual Life Res. 2024;33(10):2693\u2013704.","journal-title":"Qual Life Res"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00934-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:40Z","timestamp":1784819500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00934-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00934-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xiaoqin Yang is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Nicolae Done, Marianne Cunnington, Yipeng Gao, Jack Pfefferkorn, Leili Young-Xu, and Mei Sheng Duh are employees of Analysis Group, Inc., which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, for the conduct of the present study. Theresa Dettling is an employee of, and owns stock in, Alexion, AstraZeneca Rare Disease. Pamela L. Wolters receives research support from the Intramural Research Program of the National Institutes of Health and her contributions to this project were made as part of her official duty as an NIH federal employee, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of these authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective survey study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the Pearl IRB (IRB ID: 2024-0232). Consent to participate in the study was obtained from all participants. All participants signed an informed consent form regarding the publication of the data they contributed to this study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}